Program
ACT500
A development code. Also written as “ACT500 tablets” and “ACT500 Tablets”.
Its studies are mostly in Fatty Liver · Hepatitis B, Chronic · Non-alcoholic Fatty Liver Disease, led by Xiamen Amoytop Biotech.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Xiamen Amoytop Biotech | 32 open or running | phase 1since Nov 13, 2024 | Nov 13, 2024 | Feb 28, 2027phase 1 · NCT07462455 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 13, 2024First study: phase 1 study in Non-alcoholic Fatty Liver DiseaseFirst studyNCT06716905 · 72 enrolled · China
- Mar 4, 2026Phase 1 study in Metabolic Dysfunction-associated SteatohepatitisNCT07462455 · 24 planned · China
- May 5, 2026Phase 1 study in Hepatitis B, ChronicNCT07589400 · 24 planned · China
Ahead
- Feb 28, 2027Primary completion: phase 1 study in Metabolic Dysfunction-associated SteatohepatitisNCT07462455
- Mar 30, 2027Primary completion: phase 1 study in Hepatitis B, ChronicNCT07589400
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07589400Hepatitis B, Chronic · China | 1 | Not yet recruiting | Mar 30, 2027 | 24 |
| NCT07462455Metabolic Dysfunction-associated Steatohepatitis · China | 1 | Not yet recruiting | Feb 28, 2027 | 24 |
| NCT06716905Non-alcoholic Fatty Liver Disease · China | 1 | Completed | Sep 22, 2025 | 72 |
How it is read
Names in the registry
- “ACT500 tablets”, 3 entries
- “ACT500 Tablets”, 3 entries
Codes read as this program: ACT500.
Conditions, from the studies’ own filings
- Fatty Liver, 1 study
- Hepatitis B, Chronic, 1 study
- Non-alcoholic Fatty Liver Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.